Cover Image
市場調查報告書

帶狀皰疹:開發中產品分析

Herpes Zoster (Shingles) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232833
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
帶狀皰疹:開發中產品分析 Herpes Zoster (Shingles) - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 62 Pages
簡介

帶狀皰疹,是伴隨強烈疼痛的水痘形成性的皮疹,由水痘、帶狀皰疹病毒引起。其症狀有發熱、發冷、頭痛、關節痛等。發病要素有年齡,免疫功能低等,治療利用抗組織胺藥物和止痛藥。

本報告提供帶狀皰疹治療藥的開發情形的相關調查,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等。

簡介

  • 調查範圍

帶狀皰疹概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

帶狀皰疹:企業開發中的治療藥

帶狀皰疹:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

帶狀皰疹:企業開發中的產品

帶狀皰疹的開發治療藥的企業

  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraVir Pharmaceuticals, Inc.
  • Epiphany Biosciences, Inc.
  • Foamix Pharmaceuticals Ltd.
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • ReceptoPharm, Inc.
  • TSRL, Inc.

帶狀皰疹:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • acyclovir
  • amenamevir
  • FV-100
  • GLS-5100
  • GSK-1437173A
  • herpes zoster vaccine
  • NAL-3221
  • NAL-3223
  • RPI-78M
  • TSR-087
  • V-212
  • valomaciclovir stearate

帶狀皰疹:最近的開發平台趨勢

帶狀皰疹:暫停中的計劃

帶狀皰疹:開發中止的產品

帶狀皰疹:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9740IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1, 5, 1 and 1 respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Herpes Zoster (Shingles) - Overview
  • Herpes Zoster (Shingles) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Herpes Zoster (Shingles) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
  • ContraVir Pharmaceuticals Inc
  • Epiphany Biosciences Inc
  • Foamix Pharmaceuticals Ltd
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • SK Chemicals Co Ltd
  • XBiotech Inc
  • Herpes Zoster (Shingles) - Drug Profiles
  • acyclovir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FV-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GLS-5100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Herpes Zoster Vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • herpes zoster vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • herpes zoster vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody for Shingles - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NAL-3220 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NBP-608 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NN-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Shingles - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • V-212 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • valomaciclovir stearate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Herpes Zoster (Shingles) - Dormant Projects
  • Herpes Zoster (Shingles) - Discontinued Products
  • Herpes Zoster (Shingles) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 10, 2017: NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
  • Jun 26, 2017: NanoViricides Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology
  • Jun 21, 2017: GSK Presents Positive Results from Phase III Revaccination Study of its Candidate Shingles Vaccine Shingrix at CDC's Advisory Meeting
  • Jun 21, 2017: Positive Phase 3 for GSK's Shingles Vaccine Shingrix with Agenus QS-21 Stimulon Immune Adjuvant
  • Jun 06, 2017: NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
  • Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
  • Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
  • Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
  • Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
  • Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles
  • Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
  • Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
  • Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
  • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
  • Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Herpes Zoster (Shingles), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences Inc, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by Merck & Co Inc, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2017
  • Herpes Zoster (Shingles) - Dormant Projects, H2 2017
  • Herpes Zoster (Shingles) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Herpes Zoster (Shingles), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top